For Immediate Release
Chicago, IL – March 26, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Gilead Sciences (GILD - Free Report) , Regeneron (REGN - Free Report) , Sanofi (SNY - Free Report) , Moderna (MRNA - Free Report) and Inovio Pharmaceuticals .
Here are highlights from Wednesday’s Analyst Blog:
Top 5 Drug Stocks to Stop the Coronavirus Pandemic
Coming up with a vaccine or treatment for this pandemic is crucial for human life to go back to normality. The number of cases is growing exponentially in every corner of the globe, closing in on half a million. The world is looking to biotech companies for the cure.
Gilead Sciences’ preliminary drug, remdesivir, is seen as one of the more promising coronavirus treatments. Remdisivir received orphan drug status as of Monday by the FDA.
Regeneron and Sanofi are amid clinical trials on coronavirus patients with their drug, Kevzara. Kevzara was initially purposed for arthritis treatment but could prove as an effective treatment for COVID-19.
Moderna CEO says it could have a vaccine for health care professionals by this fall. Inovio Pharmaceuticals is also in the hunt for a coronavirus vaccine.
These firms are working tirelessly to get their vaccines and treatments to the people. It is only a matter of time before this virus anxiety is a thing of the past.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.